Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

I still can't get over how Braeburn blew this launch. It's hard to judge probuphine's acceptance at this point because it really hasn't had a chance. I don't think its any coincidence that Braeburn got a new VP of Sales in April and a new National Accounts manager in January. Perhaps one of them is being groomed to replace Sheldon. She needs to go.

Anybody notice that in the March call they described the ropinirole trial as a phase 1 safety study, but in last week's call they described it as a Phase 1/2 dosing study? That's positive at least, because they are getting Phase 1 and 2 over in a single study. Perhaps the change in trial design is what is delaying things.

In which case, why not highlight that as a positive?